ABSTRACT
Clonal hematopoiesis involves mutations in hematopoietic stem/progenitor cells, which increase the risk of cardiovascular disease, particularly under pro-inflammatory conditions. This study assessed the impact of the anti-inflammatory medication colchicine on clonal hematopoiesis in patients with recent myocardial infarction from the COLCOT trial. Participants were randomly assigned to low-dose colchicine (0.5 mg daily) or placebo, with 848 providing two DNA samples for longitudinal analysis. Targeted error-corrected sequencing was used, and 15,919 mutations were followed over a median period of 19.5 months. The results showed significantly lower variant allele fractions in the colchicine group compared to placebo (p interaction=0.03), with notable reductions in TET2 (10.3%, p=0.007; p interaction=0.001), TP53 (11.8%, p=0.001; p interaction=0.03), and SF3B1 mutations (19.9%, p=0.006; p interaction=0.005). Thus, colchicine reduced the proportion of clonal hematopoiesis mutations in patients with coronary disease, and longer-term studies with diverse populations are needed to confirm its potential benefits in mitigating related health risks.
Competing Interest Statement
J-C.T. reports research grants from AstraZeneca, Boehringer-Ingelheim, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Merck, Novartis, Novo-Nordisk, and Pfizer; honoraria from DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; minor equity interest from Dalcor Pharmaceuticals; and authorship on a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; a pending patent Early administration of low-dose colchicine after myocardial infarction, and a patent Methods for using low-dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute (J-C.T. has waived his rights in the colchicine patents and does not stand to gain financially). M-P.D. reports minor equity interest in Dalcor Pharmaceuticals. M-P.D. has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute. W.K. reports receiving consulting fees and lecture fees from AstraZeneca, Novartis, and Amgen; consulting fees from Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Corvidia Therapeutics, Esperion, Genentech, OMEICOS, Novo Nordisk, LIB Therapeutics, TenSixteen Bio, New Amsterdam Pharma and Daiichi Sankyo; lecture fees from Berlin-Chemie, Bristol-Myers Squibb, and Sanofi; and grant support and provision of reagents from Singulex, Abbott, Roche Diagnostics, and Dr Beckmann Pharma. APM received personal fees for the participation in study committees of studies sponsored by AstraZeneca, Bayer, Novartis, Sanofi, outside the present work. Other authors have nothing to declare.
Clinical Trial
NCT02551094
Funding Statement
The study was funded in part by the Health Collaboration Acceleration Fund (FACS) from the Government of Quebec (J-C.T. principal investigator and M-P.D. co-principal investigator), the Canadian Institutes of Health Research (CIHR) (application number 409752, L.B, principal investigator, J-C.T. and M-P.D. co-principal investigators), and the Montreal Heart Institute Foundation. J.C-T. and M-P.D. hold Canada Research Chairs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained from all study participants. The study was approved by the Montreal Heart Institute research ethics committee and complies with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
The CH-related mutations detected via error-corrected genomic DNA sequencing are provided in Supplementary Table 9. Due to privacy constraints, other data from COLCOT participants are not publicly accessible. However, access to these data may be requested by contacting the COLCOT study committee through Jean-Claude Tardif (jean-claude.tardif@icm-mhi.org). All additional data produced or analyzed during this study are included in the present article.
